{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:49:15Z","timestamp":1759366155812,"version":"build-2065373602"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-D-113083"],"award-info":[{"award-number":["TSGH-D-113083"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study aimed to evaluate the efficacy of lenvatinib combined with either radiotherapy (RT) or transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Conducted between December 2018 and January 2022, this retrospective study included 32 patients with advanced HCC from a single institution. The patients were divided into two treatment groups: RT plus lenvatinib (<jats:italic>n<\/jats:italic>\u2009=\u200917) and TACE plus lenvatinib (<jats:italic>n<\/jats:italic>\u2009=\u200915). The primary outcomes assessed were overall survival (OS) and infield control (IFC). Treatment modalities, patient demographics, disease characteristics, and therapeutic responses were analyzed using the Kaplan\u2013Meier method and Cox regression models to identify predictors of OS and IFC. To address baseline imbalances and competing risks, inverse-probability-of-treatment weighting (IPTW) and Fine\u2013Gray analyses were applied to better estimate IFC outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>With a median follow-up of 10.2 months, no significant difference in OS was observed between the RT and TACE groups. However, the Kaplan\u2013Meier analysis indicated significantly longer IFC durations in the RT group (<jats:italic>p<\/jats:italic>\u2009=\u20090.010), with a 1-year IFC rate of 74.7% compared to 13.2% in the TACE group. Multivariable analysis further demonstrated that the RT group was associated with better IFC outcomes (<jats:italic>p<\/jats:italic>\u2009=\u20090.023). After IPTW adjustment, the RT group retained a significant IFC benefit (<jats:italic>p<\/jats:italic>\u2009=\u20090.020). At 12 months, the cumulative infield failure rate was 61.0% in the TACE group versus 14.9% in the RT group (<jats:italic>p<\/jats:italic>\u2009=\u20090.015). Alpha-fetoprotein levels significantly declined within 3 months after RT (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) but not after TACE (<jats:italic>p<\/jats:italic>\u2009=\u20090.510). A\u2009\u2265\u20092-point deterioration in the Child\u2013Pugh score was observed in 5.9% of the RT group when compared to 26.7% of the TACE group (<jats:italic>p<\/jats:italic>\u2009=\u20090.161).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These findings suggest that RT combined with lenvatinib may offer advantages in local tumor control and potentially liver function preservation, providing a promising alternative for patients with advanced HCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14931-1","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:36:06Z","timestamp":1759228566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Wen-Yu","family":"Chuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Chien","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hua","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chou","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Shu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hsiang","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"1","key":"14931_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"14931_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-021-00245-6","volume":"7","author":"Hepatocellular carcinoma","year":"2021","unstructured":"Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):7.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"14931_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411\u201328.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"14931_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","volume":"1","author":"YR Huo","year":"2015","unstructured":"Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: A systematic review and Meta-analysis. JAMA Oncol. 2015;1(6):756\u201365.","journal-title":"JAMA Oncol"},{"key":"14931_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2020.04.024","volume":"134","author":"AS Mathew","year":"2020","unstructured":"Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, Dinniwell R, Kim J, Cho C, Ringash J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer. 2020;134:41\u201351.","journal-title":"Eur J Cancer"},{"key":"14931_CR6","doi-asserted-by":"crossref","unstructured":"Pan YX, Xi M, Fu YZ, Hu DD, Wang JC, Liu SL, Chen JB, Xu L, Zhou ZG, Liu MZ et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective propensity score matching study. Cancers (Basel). 2019;11(8):1116.","DOI":"10.3390\/cancers11081116"},{"issue":"10126","key":"14931_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"6","key":"14931_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: A review in hepatocellular carcinoma. Drugs. 2019;79(6):665\u201374.","journal-title":"Drugs"},{"issue":"3","key":"14931_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000492533","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo M. Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma. Liver Cancer. 2018;7(3):215\u201324.","journal-title":"Liver Cancer"},{"key":"14931_CR10","unstructured":"European Medicines Agency. Lenvima (lenvatinib): summary of product characteristics. http:\/\/www.ema.europa.eu\/."},{"key":"14931_CR11","unstructured":"US FDA. Lenvima\u00ae (lenvatinib) US prescribing information.\u00a0http:\/\/www.fda.gov."},{"key":"14931_CR12","unstructured":"Eisai Inc. Lenvima\u00ae (lenvatinib): Japanese prescribing information.\u00a0http:\/\/www.pmda.go.jp\/."},{"issue":"6","key":"14931_CR13","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1002\/cam4.5506","volume":"12","author":"CW Su","year":"2023","unstructured":"Su CW, Teng W, Lin PT, Jeng WJ, Chen KA, Hsieh YC, Chen WT, Ho MM, Hsieh CH, Wang CT, et al. Similar efficacy and safety between lenvatinib versus Atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer Med. 2023;12(6):7077\u201389.","journal-title":"Cancer Med"},{"issue":"6","key":"14931_CR14","doi-asserted-by":"publisher","first-page":"100591","DOI":"10.1016\/j.esmoop.2022.100591","volume":"7","author":"M Rimini","year":"2022","unstructured":"Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, et al. Atezolizumab plus bevacizumab versus lenvatinib or Sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7(6):100591.","journal-title":"ESMO Open"},{"key":"14931_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-021-01503-z","volume":"38","author":"N Une","year":"2021","unstructured":"Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C, Nishimura R, Tada H, Miyagi S, Ishida T. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol. 2021;38:1\u201314.","journal-title":"Med Oncol"},{"key":"14931_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/1471-2407-12-485","volume":"12","author":"Q Li","year":"2012","unstructured":"Li Q, Hu Y, Xi M, He L, Zhao L, Liu M. Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner. BMC Cancer. 2012;12:485.","journal-title":"BMC Cancer"},{"issue":"1","key":"14931_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, et al. Lenvatinib combined with transarterial chemoembolization as First-Line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117\u201327.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14931_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ijrobp.2011.11.058","volume":"84","author":"WY Huang","year":"2012","unstructured":"Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, Lin KT, Lin JC, Chao HL, Lin CS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;84(2):355\u201361.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"14931_CR19","doi-asserted-by":"publisher","first-page":"111266","DOI":"10.1016\/j.ejrad.2023.111266","volume":"170","author":"SH Chiu","year":"2024","unstructured":"Chiu SH, Lin HH, Feng AC, Lo CH, Hsieh CB, Chen PK, Chang WC. Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: an increased risk of liver abscess with treatment interval less than one month. Eur J Radiol. 2024;170:111266.","journal-title":"Eur J Radiol"},{"issue":"1","key":"14931_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"key":"14931_CR21","unstructured":"Common Terminology Criteria. for Adverse Events v5.0. https:\/\/www.ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"2","key":"14931_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijrobp.2019.05.066","volume":"105","author":"PC Shen","year":"2019","unstructured":"Shen PC, Chang WC, Lo CH, Yang JF, Lee MS, Dai YH, Lin CS, Fan CY, Huang WY. Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable Medium-Sized hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2019;105(2):307\u201318.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"14931_CR23","doi-asserted-by":"publisher","first-page":"888755","DOI":"10.3389\/fonc.2022.888755","volume":"12","author":"JI Yu","year":"2022","unstructured":"Yu JI, Kang W, Yoo GS, Goh MJ, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, et al. Safety and efficacy of Liver-Directed radiotherapy in combination with lenvatinib for hepatocelluar carcinoma with macroscopic tumor thrombosis. Front Oncol. 2022;12:888755.","journal-title":"Front Oncol"},{"issue":"10","key":"14931_CR24","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1007\/s00432-023-04652-y","volume":"149","author":"Q Wang","year":"2023","unstructured":"Wang Q, Ji X, Sun J, Li W, Duan X, Zhang A. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis. J Cancer Res Clin Oncol. 2023;149(10):7441\u201352.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"14931_CR25","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong R, Dinniwell RE, Kassam Z, Ringash J, Cummings B. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"14931_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"14931_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","volume":"41","author":"K Reynders","year":"2015","unstructured":"Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503\u201310.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"14931_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","volume":"68","author":"V Chew","year":"2019","unstructured":"Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, Lai L, Hazirah SN, Lim TKH, Goh BKP, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2019;68(2):335\u201346.","journal-title":"Gut"},{"issue":"5","key":"14931_CR29","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","volume":"180","author":"AA Lugade","year":"2008","unstructured":"Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-\u03b3 production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180(5):3132\u20139.","journal-title":"J Immunol"},{"key":"14931_CR30","doi-asserted-by":"publisher","first-page":"117906441876163","DOI":"10.1177\/1179064418761639","volume":"11","author":"KM Arnold","year":"2018","unstructured":"Arnold KM, Flynn NJ, Raben A, Romak L, Yu Y, Dicker AP, Mourtada F, Sims-Mourtada J. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Cancer Growth Metastasis. 2018;11:1179064418761639.","journal-title":"Cancer Growth Metastasis"},{"issue":"12","key":"14931_CR31","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, Yamada K, Hori Y, Tabata K, Takase K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993\u20134002.","journal-title":"Cancer Sci"},{"issue":"3","key":"14931_CR32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ijrobp.2022.09.060","volume":"115","author":"YS Weng","year":"2023","unstructured":"Weng YS, Chiang IT, Tsai JJ, Liu YC, Hsu FT. Lenvatinib synergistically promotes radiation therapy in hepatocellular carcinoma by inhibiting Src\/STAT3\/NF-\u03baB-Mediated Epithelial-Mesenchymal transition and metastasis. Int J Radiat Oncol Biol Phys. 2023;115(3):719\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"14931_CR33","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-06-2441","volume":"13","author":"RP Dings","year":"2007","unstructured":"Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007;13(11):3395\u2013402.","journal-title":"Clin Cancer Res"},{"issue":"5706","key":"14931_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"issue":"6","key":"14931_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12032-021-01503-z","volume":"38","author":"N Une","year":"2021","unstructured":"Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C, Nishimura R, Tada H, Miyagi S, Ishida T, et al. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol. 2021;38(6):60.","journal-title":"Med Oncol"},{"issue":"4","key":"14931_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273\u201386.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"14931_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","volume":"21","author":"AA Van der Veldt","year":"2012","unstructured":"Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012;21(1):82\u201391.","journal-title":"Cancer Cell"},{"issue":"2","key":"14931_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000526976","volume":"101","author":"N Muraishi","year":"2023","unstructured":"Muraishi N, Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, et al. The impact of lenvatinib on tumor blood vessel shrinkage of hepatocellular carcinoma during treatment: an Imaging-Based analysis. Oncology. 2023;101(2):134\u201344.","journal-title":"Oncology"},{"key":"14931_CR39","doi-asserted-by":"crossref","unstructured":"Tao Y. Rapidly developing colitis induced by combination therapy of lenvatinib and Anti-PD-1 antibody in the treatment of hepatocellular carcinoma. J Clin Images Med Case Rep. 2023;4(1):2264.","DOI":"10.52768\/2766-7820\/2264"},{"issue":"3","key":"14931_CR40","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/0300060518816875","volume":"47","author":"M Arslan","year":"2019","unstructured":"Arslan M, Degirmencioglu S. Liver abscesses after transcatheter arterial embolization. J Int Med Res. 2019;47(3):1124\u201330.","journal-title":"J Int Med Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14931-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:30:09Z","timestamp":1759275009000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14931-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14931"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14931-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan ((TSGHIRB No.: B202405172). Patient consent was waived because the data were analyzed in an anonymized format.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1449"}}